Results 201 to 210 of about 187,458 (237)

Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. [PDF]

J Chem Inf Model
Barragan AM, Ghaby K, Pond MP, Roux B.
europepmc   +1 more source

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]

Oncotarget
Patel JN, Singh J, Ghosh N.
europepmc   +1 more source

Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. [PDF]

World J Clin Oncol
Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF.   +2 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase. [PDF]

Biochemistry
Kueffer LE, Lin DY, Amatya N, Serrenho J, Joseph RE, Courtney AH, Andreotti AH.   +6 more
europepmc   +1 more source

Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer, 2014
Rudi W Hendriks, Saravanan Y Pillai
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Journal of Medicinal Chemistry, 2022
Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent
T. D. Owens, K. Brameld, E. Verner, T. Ton, Xiaoyan Li, Jiang Zhu, M. Masjedizadeh, J. M. Bradshaw, R. Hill, D. Tam, A. Bisconte, Eun Ok Kim, M. Francesco, Y. Xing, J. Shu, D. Karr, Jacob LaStant, D. Finkle, Natalie Loewenstein, H. Haberstock-Debić, Michael J. Taylor, P. Nunn, C. Langrish, D. Goldstein   +23 more
semanticscholar   +1 more source

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2019
Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.
Yunhang Guo, Ye Liu, N. Hu, D. Yu, Changyou Zhou, G. Shi, Bo Zhang, Min Wei, Jun-hua Liu, L. Luo, Zhiyu Tang, Huipeng Song, Yin Guo, X. Liu, D. Su, Shuo Zhang, Xiaomin Song, Xing Zhou, Yuan Hong, Shuaishuai Chen, Zhenzhen Cheng, S. Young, Q. Wei, Haisheng Wang, Qiuwen Wang, Lei Lv, Fan Wang, Haipeng Xu, Hanzi Sun, Haimei Xing, Na Li, Wei Zhang, Zhongbo Wang, Guodong Liu, Zhijian Sun, Dongping Zhou, Wei Li, Libin Liu, Lai Wang, Zhiwei Wang   +39 more
semanticscholar   +1 more source

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

Biochemistry, 2018
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop ...
A. Buhimschi, Haley Armstrong, M. Toure, S. Jaime-Figueroa, Timothy L Chen, A. Lehman, J. Woyach, A. Johnson, J. Byrd, C. Crews   +9 more
semanticscholar   +1 more source

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2020
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.
D. Angst, F. Gessier, P. Janser, A. Vulpetti, Rudolf Wälchli, C. Beerli, A. Littlewood-Evans, J. Dawson, B. Nuesslein‐Hildesheim, G. Wieczorek, S. Gutmann, C. Scheufler, A. Hinniger, A. Zimmerlin, Enrico G. Funhoff, R. Pulz, B. Cenni   +16 more
semanticscholar   +1 more source